YB-200

N/A

Report date: 2023/03/03 14:42:22

Base Information

Drug NameYB-200
Drug Alias NameYB-200
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 1 inhibitors
TargetsCarcinoembryonic antigen related cell adhesion molecule 1
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesYmmunobio AGLeukoCom GmbH
China Registration ClassN/A

Develop Information

Active CompaniesYmmunobio AG
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A